CureVac ends coverage after BioNTech acquisition
Following BioNTech's acquisition of CureVac, the company's shares will face Delisting as American Depositary Shares are issued to existing holders. In line with these changes, we are formally ending our equity research coverage of CureVac.
Published on 01/06/2026 at 07:20 am EST


















